Oral Corticosteroid-Related Healthcare Resource Utilization and Associated Costs in Patients with COPD
Among patients with COPD, OCS-related adverse outcomes were associated with higher attendance and costs, with a positive dose-response relationship. A graphical abstract is available with this article.
Authors
- Cono Ariti (ORCID: https://orcid.org/0000-0001-7615-0935)
- Derek Skinner (ORCID: https://orcid.org/0000-0002-7112-9317)
- Benjamin Emmanuel (ORCID: https://orcid.org/0000-0003-1769-9826)
- Mona Bafadhel (ORCID: https://orcid.org/0000-0002-9993-2478)
- Hana Müllerová (ORCID: https://orcid.org/0000-0002-0949-0101)
- Alberto Papi (ORCID: https://orcid.org/0000-0002-6924-4500)
- Gary Tse (ORCID: https://orcid.org/0000-0001-5510-1253)
- David Price (ORCID: https://orcid.org/0000-0002-9728-9992)
- Victoria Carter (ORCID: https://orcid.org/0000-0002-0333-3308)
- Jiandong Zhou (ORCID: https://orcid.org/0000-0003-3780-9033)
- Xiao Xu (ORCID: https://orcid.org/0000-0003-1083-3834)
Institutions
- AstraZeneca (United Kingdom) (GB)
- King's College London (GB)
- University of Aberdeen (GB)
- University of Ferrara (IT)
- Observational & Pragmatic Research Institute (SG)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1007/s12325-024-03024-3
- Citations
- 5
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- AstraZeneca